New biomarker could predict response to IBD treatment

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

Otsuka cuts development for AVP-786 following Phase III flop – Pharmaceutical Technology

Otsuka Pharmaceuticals ended clinical development for AVP-786 for agitation associated with Alzheimer’s disease following a negative Phase III readout. Credit: SOPA Images via Getty Images.

May 23, 2024

Breakthrough treatment improves survival rates for children with B-ALL

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children.

December 9, 2024

Adakitug by Bristol-Myers Squibb for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hormone-Sensitive Prostate Cancer.

June 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.